“Well, I’m not a doctor, I have never played one on TV, and I didn’t stay at a Holiday Inn Express last night, but here are some simple thoughts.”
https://www.biorxiv.org/content/10.1101/2021.03.19.435959v1.full
Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
Posted March 19, 2021.
This article is a preprint and has not been certified by peer review
*** begin quote ***
On 11th March 2020, coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, was declared as a global pandemic by the World Health Organization (WHO). To date, there are rapidly spreading new “variants of concern” of SARS-CoV-2, the United Kingdom (B.1.1.7), the South African (B.1.351) or Brasilian (P.1) variant. All of them contain multiple mutations in the ACE2 receptor recognition site of the spike protein, compared to the original Wuhan sequence, which is of great concern, because of their potential for immune escape. Here we report on the efficacy of common dandelion (Taraxacum officinale) to block protein-protein interaction of spike S1 to the human ACE2 cell surface receptor. This could be shown for the original spike D614, but also for its mutant forms (D614G, N501Y, and mix of K417N, E484K, N501Y) in human HEK293-hACE2 kidney and A549-hACE2-TMPRSS2 lung cells. High molecular weight compounds in the water-based extract account for this effect. Infection of the lung cells using SARS-CoV-2 spike pseudotyped lentivirus particles was efficiently prevented by the extract and so was virus-triggered pro-inflammatory interleukin 6 secretion. Modern herbal monographs consider the usage of this medicinal plant as safe. Thus, the in vitro results reported here should encourage further research on the clinical relevance and applicability of the extract as prevention strategy for SARS-CoV-2 infection.
*** end quote ***
Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
Hoai Thi Thu Tran, Nguyen Phan Khoi Le, Michael Gigl, CorinnaDawid, Evelyn Lamy
bioRxiv 2021.03.19.435959; doi:https://doi.org/10.1101/2021.03.19.435959
# – # – # – # – #
Where’s the coverage?
Like that lady doctor in Peru with peroxide, ivermectin, and vitamins, why haven’t we heard about this? Either positive or negative.
I know Big Pharma ain’t going to make a lot of money off of dandelions either but where are the Gooferment “scientists” studying this — quickly.
I found it via survival blog can’t they.
—30—
Reinke Faces Life 